The Conference Call on Q3 2026 took place on November 3, 2026
Outlook 2026 as updated on November 3, 2026
| FY 2025 | Outlook 2026 (at constant currencies) | |
| Revenue growth | EUR 19,628 million | Broadly flat |
| Operating Income growth | EUR 2,212 million | Flat to negative mid-single digit percent |
Outlook 2026 is based on current assumptions and excludes special items. Special items include the costs related to the FME25+ Program, the impacts from Legacy Portfolio Optimization, the Humacyte Remeasurements and the Tavneos Impacts as well as other effects that are unusual in nature and have not been foreseeable or not foreseeable in size or impact at the time of providing the outlook. The outlook assumes current laws, policies, regulations, and tariffs. The growth rates are based on the results 2025 excluding the costs related to the FME25+ Program (€194 M for operating income), the impacts from Legacy Portfolio Optimization (€97 M for operating income), the Legal Form Conversion Costs (€4 M for operating income) and the Humacyte Remeasurements (€90 M for operating income).
Fresenius Medical Care aspires operating income growth (CAGR) of between 3 and 7 percent between 2025 and 2028.
| FY 2025 | Aspirations 2030 (at constant currencies) | |
Care Delivery | EUR 13,736 million | Low- to mid-single digit percent |
Care Enablement | EUR 5,476 million | Mid-single digit percent |
Value-Based Care is excluded
| FY 2025 | Aspirations 2030 | |
Fresenius Medical Care Group | 11.3% | Mid-teens |
Care Delivery | 13.1% | Mid-teens |
Care Enablement | 8.1% | Mid-teens |
Value-Based Care | 0.1% | Low-single digit |
The assumed growth rates are at constant currency and exclude special items. The assumed margins exclude special items in operating income. Margin in percent of revenue.